Cytokine Release Syndrome (CRS) and Nicotine in COVID-19 Patients: Trying to Calm the Storm.
COVID-19
China
/ epidemiology
Cigarette Smoking
Coronavirus Infections
/ drug therapy
Cytokine Release Syndrome
/ drug therapy
Humans
Nicotine
/ therapeutic use
Pandemics
Pneumonia, Viral
/ drug therapy
Severity of Illness Index
alpha7 Nicotinic Acetylcholine Receptor
/ agonists
COVID-19 Drug Treatment
COVID- 19
Cytokine Release Syndrom (CRS)
SARS-CoV-2 (virus)
cholinergic anti-inflammatory pathway
lung
nicotine
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2020
2020
Historique:
received:
27
04
2020
accepted:
28
05
2020
entrez:
30
6
2020
pubmed:
1
7
2020
medline:
3
7
2020
Statut:
epublish
Résumé
SARS-CoV-2 is a new coronavirus that has caused a worldwide pandemic. It causes severe acute respiratory syndrome (COVID-19), which is fatal in many cases, and is characterized by a cytokine release syndrome (CRS). Great efforts are currently being made to block the signal transduction pathway of pro-inflammatory cytokines in order to control this "cytokine storm" and rescue severely affected patients. Consequently, possible treatments for cytokine-mediated hyperinflammation, preferably within approved safe therapies, are urgently being researched to reduce rising mortality. One approach to inhibit proinflammatory cytokine release is to activate the cholinergic anti-inflammatory pathway through nicotinic acetylcholine receptors (α7nAchR). Nicotine, an exogenous α7nAchR agonist, is clinically used in ulcerative colitis to counteract inflammation. We have found epidemiological evidence, based on recent clinical SARS-CoV-2 studies in China, that suggest that smokers are statistically less likely to be hospitalized. In conclusion, our hypothesis proposes that nicotine could constitute a novel potential CRS therapy in severe SARS-CoV-2 patients.
Identifiants
pubmed: 32595653
doi: 10.3389/fimmu.2020.01359
pmc: PMC7300218
doi:
Substances chimiques
Chrna7 protein, human
0
alpha7 Nicotinic Acetylcholine Receptor
0
Nicotine
6M3C89ZY6R
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1359Informations de copyright
Copyright © 2020 Gonzalez-Rubio, Navarro-Lopez, Lopez-Najera, Lopez-Najera, Jimenez-Diaz, Navarro-Lopez and Najera.
Références
J Epidemiol Community Health. 2017 Feb;71(2):154-161
pubmed: 27660401
Int J Antimicrob Agents. 2020 May;55(5):105954
pubmed: 32234467
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Ann Intern Med. 1997 Mar 1;126(5):364-71
pubmed: 9054280
Neuropharmacology. 2020 May 15;168:108021
pubmed: 32146229
Radiology. 2020 Apr 17;:201433
pubmed: 32301647
J Infect. 2019 Nov;79(5):401-406
pubmed: 31465780
Clin Infect Dis. 2020 Mar 16;:
pubmed: 32173725
Nature. 2003 Jan 23;421(6921):384-8
pubmed: 12508119
Signal Transduct Target Ther. 2017;2:
pubmed: 29158945
Clin Immunol. 2020 May;214:108393
pubmed: 32222466
Nature. 2000 May 25;405(6785):458-62
pubmed: 10839541
N Engl J Med. 2003 May 15;348(20):1953-66
pubmed: 12690092
Blood. 2014 Jul 10;124(2):188-95
pubmed: 24876563
Curr Drug Targets. 2012 May;13(5):707-20
pubmed: 22300038
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Allergy. 2020 Feb 19;:
pubmed: 32077115
Curr Opin Pharmacol. 2018 Jun;40:18-25
pubmed: 29331768
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Pharmacol Res. 2018 Feb;128:101-109
pubmed: 29051105
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
MMWR Morb Mortal Wkly Rep. 2020 Apr 03;69(13):382-386
pubmed: 32240123
Lancet Respir Med. 2020 Apr;8(4):e20
pubmed: 32171067
Emerg Infect Dis. 2016 Jan;22(1):49-55
pubmed: 26692185
Nat Rev Microbiol. 2019 Mar;17(3):181-192
pubmed: 30531947
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Toxicol Rep. 2020 Apr 30;:
pubmed: 32355638
Cochrane Database Syst Rev. 2012 Nov 14;11:CD000146
pubmed: 23152200
Inflammation. 2011 Aug;34(4):231-7
pubmed: 20625922